Skip to main content

VolitionRx Closes Public Offering, Raises $8.5M

NEW YORK (GenomeWeb) – VolitionRx today announced it has closed its public offering of 2,475,000 shares of stock at an offering price of $3.75 per share for net proceeds of about $8.5 million.

The firm's stock began trading on the New York Stock Exchange MKT on Feb. 6, under the ticker symbol "VNRX."

The firm said it intends to use the proceeds to fund prospective colorectal trials with Hvidovre Hospital in Denmark and an ongoing study at University Hospital in Bonn, Germany, as well as for general working capital.

National Securities, a wholly owned subsidiary of National Holdings, and Lake Street Capital Markets acted as joint book-running managers for the offering. The Benchmark Company acted as co-manager for the offering.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.